As the use of GLP-1 receptor agonists continues to expand for diabetes and obesity treatment, clinicians are beginning to examine a possible new safety signal: rare cases of nonarteritic anterior ischemic optic neuropathy (NAION).
Interest in the issue has increased following observational studies and case reports suggesting a possible association between GLP-1 medications and NAION, a condition caused by reduced blood flow to the optic nerve that can lead to sudden vision loss. Although the absolute risk appears to be small, the widespread use of these medications means that even rare adverse events are drawing increased scrutiny.
Experts emphasize that current evidence does not establish a causal relationship and that the overall benefits of GLP-1 therapy remain substantial. Still, clinicians say the reports highlight the importance of recognizing symptoms quickly and understanding which patients may already carry underlying risk factors for optic nerve ischemia.
A Refresher on NAION
NAION is the most common acute optic neuropathy in adults older than 50 years. The condition occurs when blood flow to the anterior portion of the optic nerve becomes compromised, leading to ischemic injury.
“Nonarteritic anterior ischemic optic neuropathy is essentially an ischemic event that affects the head of the optic nerve,” said Kevin Gendreau, MD, an obesity medicine physician at the Weight & Wellness Center at Signature Healthcare in Brockton, Massachusetts.Patients typically present with sudden, painless vision loss in one eye, often noticed upon waking.
“Patients describe blurry vision, dim vision, or visual field deficits,” Gendreau said. “Initially, the presentation can be subtle, which can sometimes lead to delays in care.”
Pravin Date, MD, a primary care physician at SCV Medical Group in Santa Clarita, California, and a hospitalist at Kaiser Permanente Panorama City Medical Center in Panorama City, California, described a similar presentation.
Because permanent visual loss can occur, clinicians emphasize that any abrupt change in vision should be treated as an urgent medical issue.
Gendreau said that NAION is estimated to affect roughly two to ten individuals per 100,000 people annually, although the risk increases with age and vascular disease. The condition is typically unilateral at presentation, though patients who experience NAION in one eye may carry a higher risk of developing it in the other eye over time.
Risk Overlap With Metabolic Disease
A range of systemic and anatomical factors are known to increase the risk for NAION.
“Traditional risk factors include diabetes, hypertension, sleep apnea, and a ‘crowded’ optic disc anatomy,” Date said.
Many of these same conditions are common among patients treated with GLP-1 medications.
“Patients who may be predisposed to NAION are often the same individuals we see in metabolic and weight-loss centers,” Gendreau said. “People with diabetes, hypertension, obstructive sleep apnea, or other vascular risk factors already carry a higher baseline risk of ischemic events.”
Some investigators have also proposed physiologic mechanisms that could theoretically contribute to optic nerve ischemia during treatment.
“A rapid change or correction in blood sugar could be one proposed mechanism,” Gendreau said. “Rapid changes in blood pressure or volume status could also contribute, in theory, although the data showing this link is lacking.”
What Ophthalmologists Are Seeing
Ophthalmologists say patient questions about the issue have increased as awareness of the potential association has grown.
“When patients ask me about ‘eye strokes’ and weight-loss medications, I try to explain it in a balanced way,” said Yuna Rapoport, MD, an ophthalmologist and refractive cornea surgeon at Manhattan Eye in New York City.
Some researchers have proposed that physiologic changes associated with GLP-1 medications — including shifts in blood pressure, fluid balance, or blood sugar — could theoretically reduce optic nerve perfusion in susceptible individuals.
“These medications can lead to changes in blood pressure, fluid balance, or blood sugar levels,” Rapoport said. “In certain people that may reduce blood flow to the optic nerve, especially overnight when blood pressure naturally dips.”
However, she said that the risk appears to occur primarily among patients who already have underlying vascular risk factors.
Questions About Drug Dose
Some clinicians have also questioned whether risk could vary between different GLP-1 formulations or doses.
“One of the medications that has been discussed more is Wegovy,” Rapoport said. “It uses a higher dose of semaglutide than Ozempic, which may lead to stronger metabolic and fluid shifts.”
Analyses of pharmacovigilance data have suggested that reports of ischemic optic neuropathy appear most frequently in association with semaglutide products.
“In a large global analysis of FDA adverse-event reports, semaglutide overall showed an association with ischemic optic neuropathy,” Rapoport said. “The signal appeared strongest with Wegovy, suggesting the risk may be dose-related rather than purely drug-specific.”
Evidence Remains Observational
Despite the emerging discussion, experts stress that current evidence linking GLP-1 medications to NAION remains limited.
“Currently, the evidence linking GLP-1 agonists to NAION is limited and observational,” Gendreau said. “Retrospective studies and case reports have raised the question of an association, but that’s different from proving definitive causation.”
Date echoes that interpretation.
“Regarding GLP-1 medications, the current signal appears to come primarily from observational data and case reports, which means the association should be interpreted cautiously,” he said.
Because these medications are prescribed to millions of patients, rare events may appear more frequently simply due to scale.
“These drugs are now used by millions of patients,” Date said. “So rare events may emerge simply through scale.”
At present, the available evidence suggests a possible association but not a confirmed causal relationship.
Balancing Risk and Benefit
As GLP-1 receptor agonists continue to be used by a growing number of patients worldwide, experts say clinicians should expect increased attention to rare adverse events.
“As these medications become more widely used, we are naturally going to see more discussion of rare events,” Gendreau said.
Date emphasized that potential safety signals should be considered alongside the substantial clinical benefits these medications provide.
“GLP-1 therapies are delivering substantial population-level benefits in obesity and metabolic disease,” he said. “While potential adverse signals deserve careful study, clinicians should weigh these against the well-established reductions in cardiovascular and metabolic risk seen with these medications.”
Awareness of symptoms, attention to existing vascular risk factors, and prompt referral for evaluation of sudden visual changes remain the most practical steps clinicians can take while researchers continue to study the possible association between GLP-1 therapies and ischemic optic neuropathy.
No reported disclosures.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.